Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences
Retrieved on:
Wednesday, May 24, 2023
Clinical pharmacology, Computing, Society, Doctor of Pharmacy, Drug development, Senior, Artificial intelligence, Pharmacy, Doctor of Philosophy, Canadian Society for Pharmaceutical Sciences, Patient, Machine learning, Fatty liver disease, Science, Conditional sentence, HEPA, Pharmacology, Report of the 1st Annual Symposium on Relaxed Improvisation, Quantitative systems pharmacology, CSPS, Medical device
Title: Simulation in drug development: Clinical Pharmacology, Quantitative Systems Pharmacology Artificial Intelligence and Beyond?
Key Points:
- Title: Simulation in drug development: Clinical Pharmacology, Quantitative Systems Pharmacology Artificial Intelligence and Beyond?
- Session: 9:00 – 11:00 AM ET SESSION 6: AI and Computer Technology in the Sciences
Dr. Mayo commented, “Artificial intelligence and machine learning are here, and are being integrated into drug development. - AI-POWR™ is Hepion’s proprietary AI/ML platform designed to speed up drug development by detecting a priori patients who will respond to our lead compound, rencofilstat.
- CSPS has graciously allowed us the opportunity to describe the integration of AI-POWR™ into all aspects of our clinical pharmacological programs.”
A copy of the presentation will be accessible on the Company’s website at www.hepionpharma.com under “Publications” in the Pipeline section.